Compare POET & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | XNCR |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 775.8M | 881.9M |
| IPO Year | 2008 | 2013 |
| Metric | POET | XNCR |
|---|---|---|
| Price | $6.27 | $12.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | ★ 8.7M | 793.3K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $848.96 | N/A |
| Revenue Next Year | $700.00 | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $3.53 | $6.92 |
| 52 Week High | $9.41 | $18.69 |
| Indicator | POET | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 52.24 |
| Support Level | $6.00 | $12.29 |
| Resistance Level | $7.31 | $12.87 |
| Average True Range (ATR) | 0.48 | 0.81 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 87.07 | 61.61 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.